Register Your Interest
English
Lorem ipsum dolor sit amet consectetur. Nibh diam vitae quisque egestas eu nulla risus. In enim in nisl natoque. Accumsan a sit feugiat amet imperdiet vel vel.
View More
Friedreich Ataxia (FA) is a serious, rare and debilitating disease that affects the brain, nerves, heart, and other organs. FA has a direct impact on day-to-day function. Treatment options are limited and there is no cure.
That’s why we’re conducting the Friedrich Ataxia DT-216P2 study to assess a potential new treatment for FA. This study aims to better understand how the body interacts with this potential new treatment, as well as safety and tolerability in people living with FA.
This study may involve 4 two-night stays (a week apart) at the Doherty Clinical Trials unit, 9 clinic follow-up visits and 1 phone call over approximately 2 months.
.png)
4 overnight stays, 9 clinic visits & 1 phone call over approximately 2 months
Up to $11,500
Be aged 18 – 65 years old
All genders welcome
Genetically confirmed diagnosis of FA
People with a bleeding disorder, low platelet count or a significant skin or muscle condition will not be able to take part
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}